Strategic collaboration announced in China to accelerate the development of bacterial drugs
A strategic cooperation between Porton Advanced Solutions and Suzhou Royaltech Med Co., Ltd was announced…
August 29, 2022 - 2 minutes
mRNA: A New Technology Moving into the Mainstream
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
Show More
Editor's Picks for mRNA technology
- Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
- The COVID-19 pandemic has driven RNA therapeutics into the mainstream
- EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19
- Next-Generation mRNA Vaccine Technology Unveiled in Series A Round
- Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportLatest mRNA technology Articles
Millions in funding and new board members for Belgian mRNA company
The mRNA technologies company eTheRNA has raised €39 million ($38.7 million) in series B2 financing.…
August 24, 2022 - 3 minutes
IVI and Moderna sign MOU for vaccine R&D
The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and…
July 20, 2022 - 2 minutes
Cancer therapeutics company’s double win with $25M funding, and appointment of new board member
An mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of…
July 8, 2022 - 3 minutes
Exyte Builds mRNA Competence Center for WACKER in Germany
A messenger ribonucleic acid (mRNA) competence center is being built at the Halle Biotech site…
July 6, 2022 - 4 minutes
The COVID-19 pandemic has driven RNA therapeutics into the mainstream
As messenger RNA vaccines save lives around the world, and RNA interference drugs are greenlit…
July 4, 2022 - 8 minutes
Covid and malaria vaccines on track for mass production in Rwanda
Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This…
June 24, 2022 - 3 minutes
New agreement could lead to first African-owned COVID-19 vaccine
A year after the creation of the mRNA Vaccine Technology Transfer Hub, two biotech companies…
June 21, 2022 - 4 minutes
Eurocine Vaccines expands portfolio to develop HSV-2 vaccine
Swedish company Vaccines AB (Eurocine Vaccines) has entered into a research and collaboration agreement with…
June 15, 2022 - 2 minutes
Ziphius Vaccines and University of Antwerp to work on RNA-based delivery methods
Belgian biopharma firm Ziphius Vaccines is set to collaborate with the University of Antwerp to…
June 9, 2022 - 3 minutes
Therapeutic RNA company receives additional funding
UK biotech company Transine Therapeutics, which is developing a novel class of therapeutic RNAs, has…
May 31, 2022 - 2 minutes
Ethris Raises €23M to Make Inhaled Respiratory Therapies from mRNA
Thanks to Covid-19 vaccines, messenger RNA (mRNA) technology has reached the mainstream. With a €23.4M…
February 1, 2022 - 3 minutes
